A new study has found that telavancin, a current treatment for hospital-acquired pneumonia, could be a potential treatment against methicillin-resistant Staphylococcus aureus (MRSA) in patients with cystic fibrosis.
[maxbutton id=”1″ url=”http://info.respiratory-therapy.com/regform” text=”SUBSCRIBE TO NEWS” ]
When testing the activity of the drug against 23 MRSA strains, the investigators observed intermediate resistance to ceftaroline (CPT)—a new beta-lactam antibiotic that targets PBP 2a in MRSA—in 20 of the strains, and high-level resistance to CPT in 3 of the strains. The authors note that although high levels of resistance to CPT is rare, intermediate resistance is more common in patients who have chronic infections.
The investigators assessed the in vitro effectiveness of TLV compared with DAP, VAN, and CPT using time-kill experiments. They found that TLV showed activity against all tested strains and displayed rapid bactericidal activity as well. The activity profile for the drug at a free serum concentration of 8 mg/liter showed that TLV performed better than VAN (16 mg/liter), LZD (10.4 mg/liter), and CPT (16 mg/liter).